eNewsChannels NEWS: (IRVING, Texas) -- BioTE(R) Medical announces a forum of medical experts gathering before the Age Management Medicine Group (AMMG) to form consensus on testosterone therapy in women. The AMMG conference runs April 27-30, 2017 in Orlando, Florida.

eNewsChannels NEWS: (LAS VEGAS, Nev.) -- C Diff Foundation's 5th Annual International C.diff. Awareness Conference and Health EXPO will be hosted in Las Vegas, Nev. on November 9 & 10, 2017 at UNLV-Thomas and Mack Center. A panel of C. diff. survivors will join world-renowned experts delivering presentations on health care topics pertaining to the most common pathogen identified, a leading healthcare-associated infection (HAI) in U.S. hospitals alone: Clostridium difficile (C.diff.).

eNewsChannels NEWS: (CORTE MADERA, Calif.) -- Dr. Don Harte, chiropractic activist, says Trump's new panel, headed by Chris Christie, to deal with the opioid epidemic, is "philosophically and scientifically dead wrong." Dr. Harte declares, "The reason for this epidemic is clear. Orthopedists and other doctors freely prescribe Oxycontin, Fentanyl, Soma and other opioid drugs, get their patients addicted."

eNewsChannels NEWS: (AURORA, Colo.) -- Extreme Muscle Products (EMP) have announced the launch of its first formulation available for purchase, a product called Q-Meric. EMP is a newly created Colorado-based company focusing on health, wellness and athletic performance, with an emphasis on products that have synergistic effects.

eNewsChannels NEWS: (PORTLAND, Ore.,) -- Paragon BioTeck, Inc. announces a monumental ruling handed down by the United States Patent and Trademark Office (USPTO) affirming claims made by Paragon in the patent for its R-phenylephrine hydrochloride formulation. Paragon is a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices and therapies.

NEWS: (NEW YORK, N.Y.) National lawfirm Weitz and Luxenberg, P.C., said today it hopes potentially fatal side effects associated with SGLT2 inhibitor drugs will be reported to consumers faster, since people taking these next-generation diabetes medications deserve to be notified of the health dangers shortly after they have been reported to the U.S. Food and Drug Administration (FDA).

NEWS: Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, will sponsor a special reception during the J.P. Morgan 2016 Healthcare Conference, being held in San Francisco, Jan. 11-14. The conference, which is now in its 34th year, is an invitation-only event intended to create an environment of collaboration by bringing together stakeholders in the corporate, investor and financial sectors to learn about and explore market and sector trends.

NEWS: Weitz and Luxenberg, P.C., today announced that the firm has expanded the scope of its investigation into SGLT2 inhibitor drug injuries. SGLT2 inhibitor drugs include Invokana and others listed below. This move will allow the nationally known mass tort law and personal injury firm to focus on cases where people taking SGLT2 inhibitors were hospitalized after developing urosepsis (serious infection of the blood) or pyelonephritis (infection of the kidneys) from SGLT2 inhibitor-associated urinary tract infections.

NEWS: Philosys, Inc., the maker of Gmate(R) products, announced today that the U.S. Food and Drug Administration (FDA) has approved clearance for the Gmate SMART Blood Glucose Monitoring System and App for Android(TM). The Gmate SMART is a small, portable blood glucose meter that plugs into the headphone jack of a smartphone and provides fast and accurate blood glucose test results.

NEWS: Council for Vaccine Safety, and A Voice for Choice, in collaboration with community leaders, announce that on October 24, 2015 at 12 noon, protesters will rally at Frank Ogawa Plaza in Oakland, Calif. in solidarity with the Truth, Transparency and Freedom Rally happening on the same day at the CDC in Atlanta, Georgia.